Rafarma To Expand Proton Therapy Centers
Rafarma Pharmaceuticals (RAFA) has announced its active discussions with the City Scientific University of Istanbul to establish a nuclear medicine and proton therapy center. This initiative aims to enhance cancer treatment, as proton therapy can deliver precise doses to challenging tumors with fewer side effects compared to traditional therapies. The company aspires to lead the development of multiple proton therapy centers, supported by insights from Modern Nuclear Technologies LLC on the benefits of this advanced treatment option.
- Active meetings with the City Scientific University of Istanbul to establish a proton therapy center.
- Proton therapy presents a less invasive treatment option with fewer side effects for cancer patients.
- Plans for multiple proton therapy centers indicate strong business development potential.
- None.
Nicosia, Cyprus, May 07, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce that RAFA is in active meetings the City Scientific University of Istanbul (Turkey) (https://cerrahpasa.istanbulc.edu.tr) to establish a nuclear medicine and proton therapy center at the university. In developed countries, up to
Proton therapy precisely targets even the most difficult to treat tumors and allows higher doses of radiation to be delivered with fewer side effects. Unlike treatment with conventional X-ray therapy, treatment with proton therapy can be achieved using fewer radiation beams, and is non-invasive.
Rafarma is looking to lead the industry in the development of multiple proton therapy centers, with many more projects in the pipeline.
Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For more information contact:
RAFARMA
(307) 429-2029
Attachment
FAQ
What is Rafarma Pharmaceuticals (RAFA) planning with the City Scientific University of Istanbul?
What are the benefits of proton therapy mentioned by Rafarma?
What is Rafarma's vision for proton therapy centers?
What insights has Rafarma received regarding proton therapy?
